

- (a) ThrSerGlyMetGlyValSer: SEQ ID NO: 22,  
(b) HisIleTyrTrpAspAspAspLysArgTyrAsnProSerLeuLysSer: SEQ ID NO: 24, and  
(c) ArgGluThrValPheTyrTrpPheAspVal: / SEQ ID NO: 26.

B4  
8. (Amended) The fusion protein according to claim 1 wherein the complementarity determining regions (CDRs) for the light chain comprise:

- (a) LeuAlaSerGlnSerValAspTyrAspGlyAspSerTyrMetAsn: SEQ ID NO: 16,  
(b) AlaAlaSerAsnLeuGluSer: SEQ ID NO: 18, and  
(c) GlnGlnSerAsnGluAspProProArg: SEQ ID NO: 28.

9. (Amended) The fusion protein according to claim 1 wherein the complementarity determining regions (CDRs) for the light chain comprise:

- (a) LysAlaSerGlnSerValAspTyrAspGlyAspSerTyrMetAsn: SEQ ID NO: 16,  
(b) AlaAlaSerAsnLeuGluSer: SEQ ID NO: 18, or  
(c) GlnGlnSerAsnGluAspProProThr: SEQ ID NO: 20.

B5  
14. (Amended) A humanized antibody comprising a heavy chain and a light chain, said antibody characterized by a dissociation constant equal to or less than  $2 \times 10^{-10}$  M for human IL4, wherein the framework regions of said heavy and light chains are obtained from at least one selected human antibody and the amino acid and the amino acid sequences of the complementarity determining regions of said chain are obtained from a non-human neutralizing monoclonal antibody specific for human IL4 characterized by a dissociation constant equal to or less than  $2 \times 10^{-10}$  M for human IL4.

B6  
16. (Amended) A chimeric antibody comprising a heavy chain and a light chain, said antibody characterized by a dissociation constant equal to or less than about  $2 \times 10^{-10}$  M for human IL4, wherein the amino acid sequences of the complementarity determining regions of said heavy chain and said light chain are obtained from a non-human neutralizing monoclonal antibody specific for human IL4 characterized by a dissociation constant equal to or less than about  $2 \times 10^{-10}$  M for human IL4.